← All trials
NCT04718025
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 1, 2021
- Primary completion
- Jun 30, 2023
- Completion date
- Jun 30, 2023
- First posted
- Jan 22, 2021
- Last posted
- Jul 28, 2021
- Enrollment
- 4500
- Arms / groups
- 3 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Nicolaus Copernicus UniversityLead sponsor
- Nicolaus Copernicus UniversityReponsible party - principal investigator
- Nicolaus Copernicus UniversityOverall official - principal investigator
- Government of PolandCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.